Head-to-head evidence
Glecirasib vs HBI-2438
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
Glecirasib
Developed by Jacobio Pharmaceuticals
NCT05002270 · Phase 1/2 · completed
The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.
Next expected readout: March 2027 · NCT05288205 (registry estimate)
HBI-2438
Developed by HUYABIO International, LLC.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05485974 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glecirasib's landscape · HBI-2438's landscape